Form 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report:

 

February 28, 2005

(Date of earliest event reported)

 

 

CELL THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Washington   001-12465   91-1533912

(State or other jurisdiction of

incorporation or organization)

   (Commission File Number)  

(I.R.S. Employer

Identification Number)

 

501 Elliott Avenue West, Suite 400

Seattle, Washington 98119

(206) 282-7100

(Address including zip code, and telephone number, including

area code, of Registrant’s principal executive offices)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 2.02. Results of Operations and Financial Condition.

 

The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

On February 28, 2005, Cell Therapeutics, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2004 and certain other information. The full text of the press release is set forth in Exhibit 99.1 hereto.

 

Item 9.01. Financial Statements and Exhibits.

 

  (c) Exhibits.

 

The following exhibit is furnished with this report on Form 8-K:

 

99.1   Press Release dated February 28, 2005.

 

 

-1-

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

    CELL THERAPEUTICS, INC.

Date: February 25, 2005

   By:  

/s/ Louis A. Bianco

        Louis A. Bianco
        Executive Vice President, Finance and Administration

 

 

-2-

EXHIBIT INDEX

 

Exhibit
Number
  

Description

99.1   Press Release dated February 28, 2005

 

-3-